Medical devices, healthcare technology and the business of care
510(k) clearance · K253909

NeoPEX Pre-Mixed Obturation Paste

NuSmile, Ltd. · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONK253909

What did the FDA decide?

On September 4, 2026, FDA recorded a substantial equivalence determination (SESE) for NeoPEX™ Pre-Mixed Obturation Paste, submitted by NuSmile, Ltd. under K253909. The device is a non-sterile, premixed hydraulic calcium silicate paste containing calcium hydroxide, supplied in a prefilled syringe with disposable dispensing tips; the summary states it hardens in moisture, creates an alkaline environment, releases calcium, and is radiopaque. It is classified under 21 CFR 872.3820 with product codes KIF and EJK.

The submission lists nRoot SP (K250710) as primary predicate, with nRoot BP (K251465), MTA 2.3 (K181917) and UltraCal XS (K211905) as reference devices. The summary reports similar form, delivery, composition, setting per ISO 6876, calcium release and pH above 11, and states no clinical studies were required. SE is a clearance, not a PMA approval. The source does not provide the full decision letter text, so any conditions beyond the quoted QMSR reminder remain unknown.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Dental
Decision date
Sep 4, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K253909
Regulatory pathway
510(k) premarket notification
Applicant
NuSmile, Ltd.
Product code
KIF
Decision code
SESE
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Resin, Root Canal Filling.

Applicant
NuSmile, Ltd.
Product code
KIF
FDA device class
2

FDA decision timeline

  1. K253909 received

    Application receipt date recorded by FDA.

  2. K253909 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code KIF

Product / regulatory recordCompanyPathwayDecision dateSource
BCS Device Pte., Ltd.510(k) clearanceOct 16, 2026FDA
Vioseal XK262050
Spident Co., Ltd.510(k) clearanceSep 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

NuSmile, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Houston, TX

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records